INFORMING VALUE-BASED PROCUREMENT DECISIONS THROUGH SOCIAL RETURN ON INVESTMENT: THE CASE OF IMMUNOGLOBULIN THERAPY IN PRIMARY IMMUNODEFICIENCIES
Author(s)
Laurence UNDREINER, PhD1, Batyrkhan Kuatov, MA2, Melike Inkaya Taskin, Sr., BSc, MBA3, Juliette Placer, MSc4, Bertrand Tehard, PhD5.
1CSL Behring, Paris, France, 2Director HEOR, Global Market Access, CSL Behring, Bern, Switzerland, 3CSL BEHRING, Istanbul, Turkey, 4Rweality, Paris, France, 5Vyoo Agency, Paris, France.
1CSL Behring, Paris, France, 2Director HEOR, Global Market Access, CSL Behring, Bern, Switzerland, 3CSL BEHRING, Istanbul, Turkey, 4Rweality, Paris, France, 5Vyoo Agency, Paris, France.
OBJECTIVES: This study aimed to support the evolution of hospital procurement toward Value-Based Procurement (VBP) by applying a Social Return on Investment (SROI) framework capturing value dimensions beyond acquisition price. Immunoglobulin therapy in primary immunodeficiencies was used as a case study to illustrate this approach for critical medicine with clinical, organizational, and societal implications.
METHODS: A SROI model was developed over a three-year time horizon in France. SROI is expressed as a ratio which, when greater than 1, indicates a positive return, meaning that the intervention generates socio-economic value that exceeds its cost. The analysis compared patients treated with immunoglobulin therapy with patients untreated or managed with alternative therapies. The model included product-related costs, healthcare resource utilization, and societal parameters. Sensitivity analyses explored alternative assumptions regarding indirect costs.
RESULTS: Immunoglobulin therapy generated a positive socio-economic return over three years, with an overall SROI ratio of 1.30. This ratio reflected total economic and societal savings of €581.9M against a total investment in immunoglobulin replacement therapy of €447.5M. Beyond direct economic savings, organizational (reductions in healthcare utilization, improvements in the organization of care pathways) and societal savings (gains related to the productivity of patients and caregivers) represented a substantial share of total value, contributing significantly to the observed SROI. By monetizing these outcomes, the framework illustrates how procurement decisions can incorporate broader value dimensions beyond acquisition cost.
CONCLUSIONS: These findings demonstrate that immunoglobulin therapy generates substantial socio-economic benefits over the medium term, supporting its relevance beyond a strictly short-term budgetary perspective. SROI offers a practical pathway to support VBP by structuring and monetizing broader dimensions of value beyond acquisition price. From a policy perspective, these results can inform procurement processes based on the Most Economically Advantageous Tender (MEAT) principle by providing quantified evidence to support the inclusion of non-price criteria.
METHODS: A SROI model was developed over a three-year time horizon in France. SROI is expressed as a ratio which, when greater than 1, indicates a positive return, meaning that the intervention generates socio-economic value that exceeds its cost. The analysis compared patients treated with immunoglobulin therapy with patients untreated or managed with alternative therapies. The model included product-related costs, healthcare resource utilization, and societal parameters. Sensitivity analyses explored alternative assumptions regarding indirect costs.
RESULTS: Immunoglobulin therapy generated a positive socio-economic return over three years, with an overall SROI ratio of 1.30. This ratio reflected total economic and societal savings of €581.9M against a total investment in immunoglobulin replacement therapy of €447.5M. Beyond direct economic savings, organizational (reductions in healthcare utilization, improvements in the organization of care pathways) and societal savings (gains related to the productivity of patients and caregivers) represented a substantial share of total value, contributing significantly to the observed SROI. By monetizing these outcomes, the framework illustrates how procurement decisions can incorporate broader value dimensions beyond acquisition cost.
CONCLUSIONS: These findings demonstrate that immunoglobulin therapy generates substantial socio-economic benefits over the medium term, supporting its relevance beyond a strictly short-term budgetary perspective. SROI offers a practical pathway to support VBP by structuring and monetizing broader dimensions of value beyond acquisition price. From a policy perspective, these results can inform procurement processes based on the Most Economically Advantageous Tender (MEAT) principle by providing quantified evidence to support the inclusion of non-price criteria.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE565
Topic
Economic Evaluation
Topic Subcategory
Novel & Social Elements of Value
Disease
Rare & Orphan Diseases